In Vitro activity of a new isothiazoloquinolone, ACH-702, against mycobacterium tuberculosis and other mycobacteria

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 5, 2010, Pages 2188-2190

  Molina Torres, Carmen A ^a   Ocampo Candiani, Jorge ^a   Rendón, Adrian ^a   Pucci, Michael J ^b   Vera Cabrera, Lucio ^a  

^a HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^b Achillion Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACH 702; CIPROFLOXACIN; GATIFLOXACIN; ISONIAZID; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SPARFLOXACIN; UNCLASSIFIED DRUG;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM AVIUM; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM INTRACELLULARE AVIUM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG DESIGN; DRUG RESISTANCE, BACTERIAL; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIA, ATYPICAL; MYCOBACTERIUM AVIUM; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM CHELONAE; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM KANSASII; MYCOBACTERIUM TUBERCULOSIS; QUINOLONES; THIAZOLES;

EID: 77951249362     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01603-09     Document Type: Article

References (33)

1. Akcali, S., S. Surucuoglu, C. Cicek, and B. Ozbakkaloglu. 2005. In vitro activity of ciprofloxacin, ofloxacin and levofloxacin against Mycobacterium tuberculosis. Ann. Saudi Med. 25:409-412.
2. Alcaide, F., L. Calatayud, M. Santín, and R. Martín. 2004. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii. Antimicrob. Agents Chemother. 48:4562-4565.
3. Alvirez-Freites, E. J., J. L. Carter, and M. H. Cynamon. 2002. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 46:1022-1025.
4. Blumberg, H. M., W. J. Burman, R. E. Chaisson, C. L. Daley, S. C. Etkind, L. N. Friedman, P. Fujiwara, M. Grzemska, P. C. Hopewell, M. D. Iseman, R. M. Jasmer, V. Koppaka, R. I. Menzies, R. J. O'Brien, R. R. Reves, L. B. Reichman, P. M. Simone, J. R. Starke, and A. A. Vernon. 2003. American Thoracic Society/Centers for Dis. Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167:603-662.
5. Brighty, K. E., and T. D. Gootz. 2000. Chemistry and mechanism of action of the quinolone antibacterials, p. 34-82. In V. T. Andriole (ed.), The quinolones, 3rd ed. Academic, San Diego, CA.
6. Brown-Elliott, B. A., R. J. Wallace, Jr., C. J. Crist, L. Mann, and R. W. Wilson. 2002. Comparison of in vitro activities of gatifloxacin and ciprofloxacin against four taxa of rapidly growing mycobacteria. Antimicrob. Agents Chemother. 46:3283-3285.
7. Chu, D. T. W., P. B. Fernandes, A. K. Claiborne, L. L. Shen, and A. G. Pernet. 1989. Structure-activity relationships in quinolone antibacterials: replacement of the 3-carboxylic acid group, p. 37-45. In P. B. Fernandes (ed.), Quinolones. J. R. Prous, Barcelona, Spain.
8. Chu, D. T. W., P. B. Fernandes, A. K. Claiborne, L. Shen, and A. G. Pernet. 1988. Structure-activity relationships in quinolone antibacterials: design, synthesis and biological activities of novel isothiazoloquinolones. Drugs Exp. Clin. Res. 14:379-383.
9. Franzblau, S. G., R. S. Witzig, J. C. McLaughlin, P. Torres, G. Madico, A. Hernandez, M. T. Degnan, M. B. Cook, V. K. Quenzer, R. M. Ferguson, and R. H. Gilman. 1998. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay. J. Clin. Microbiol. 36:362-366.
10. Fung-Tomc, J., B. Minassian, B. Kolek, T. Washo, E. Huczko, and D. Bonner. 2000. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin. J. Antimicrob. Chemother. 45:437-446.
11. Gillespie, S. H., and O. Billington. 1999. Activity of moxifloxacin against mycobacteria. J. Antimicrob. Chemother. 44:393-395.
12. Griffith, D. E., T. Aksamit, B. A. Brown-Elliott, A. Catanzaro, C. Daley, F. Gordin, S. M. Holland, R. Horsburgh, G. Huitt, M. F. Iademarco, M. Iseman, K. Olivier, S. Ruoss, C. F. von Reyn, R. J. Wallace, Jr., and K. Winthrop. 2007. American Thoracic Society. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med. 175:367-416.
13. Hashimoto, A., G. C. G. Pais, Q. Wang, E. Lucien, C. D. Incarvito, M. Deshpande, B. J. Bradbury, and J. A. Wiles. 2007. Practical synthesis and molecular structure of a potent broad-spectrum antibacterial isothiazoloquinolone. Org. Process Res. Dev. 11:389-398.
14. Hu, Y., A. R. M. Coates, and D. A. Mitchison. 2003. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47:653-657.
15. Jacobs, M. R. 2004. Fluoroquinolones as chemotherapeutics against mycobacterial infections. Curr. Pharm. Des. 10:3213-3220.
16. Ji, B., N. Lounis, C. Maslo, C. Truffot-Pernot, P. Bonnafous, and J. Grosset. 1998. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 42:2066-2069.
17. Kohno, Y., H. Ohno, Y. Miyazaki, Y. Higashiyama, K. Yanagihara, Y. Hirakata, K. Fukushima, and S. Kohno. 2007. In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. Antimicrob. Agents Chemother. 51:4071-4076.
18. Leysen, D. C., A. Haemers, and S. R. Pattyn. 1989. Mycobacteria and the new quinolones. Antimicrob. Agents Chemother. 33:1-5.
19. Mwinga, A., and F. P. Bernard. 2004. Prospects for new tuberculosis treatment in Africa. Trop. Med. Int. Health 9:827-832.
20. National Committee for Clinical Laboratory Standards. 2003. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard. NCCLS document M24-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
21. Pucci, M. J., J. Cheng, S. D. Podos, C. L. Thoma, J. A. Thanassi, D. D. Buechter, G. Mushtaq, G. A. Vigliotti, B. J. Bradbury, and M. Deshpande. 2007. In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens. Antimicrob. Agents Chemother. 51:1259-1267.
22. Rastogi, N., V. Labrousse, and K. S. Goh. 1996. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr. Microbiol. 33:167-175.
23. Rodriguez Diaz, J. C., M. Lopez, M. Ruiz, and G. Royo. 2003. In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria. Int. J. Antimicrob. Agents 21:585-588.
24. Shandil, R. K., R. Jayaram, P. Kaur, S. Gaonkar, B. L. Suresh, B. N. Mahesh, R. Jayashree, V. Nandi, S. Bharath, and V. Balasubramanian. 2007. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob. Agents Chemother. 51:576-582.
25. Telenti, A., F. Marchesi, M. Balz, F. Bally, E. C. Böttger, and T. Bodmer. 1993. Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis. J. Clin. Microbiol. 31:175-178.
26. Tomioka, H., C. Sano, K. Sato, and T. Shimizu. 2002. Antimicrobial activities of clarithromycin, gatifloxacin and sitafloxacin, in combination with various antimycobacterial drugs against extracellular and intramacrophage Mycobacterium avium complex. Int. J. Antimicrob. Agents. 19:139-145.
27. Vera-Cabrera, L., M. J. Pucci, C. A. Molina-Torres, P. Rivera, O. Welsh, and J. Ocampo-Candiani. 2009. In vitro activity of ACH 702 against Nocardia brasiliensis, abstr. F1-1974. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother.
28. Wang, Q., E. Lucien, A. Hashimoto, G. C. G. Pais, D. M. Nelson, Y. Song, J. A. Thanassi, C. W. Marlor, C. L. Thoma, J. Cheng, S. D. Podos, Y. Ou, M. Deshpande, M. J. Pucci, D. D. Buechter, B. J. Bradbury, and J. A. Wiles. 2007. Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions. J. Med. Chem. 50:199-210.
29. Wiles, J. A., A. Hashimoto, J. A. Thanassi, J. Cheng, C. D. Incarvito, M. Deshpande, M. J. Pucci, and B. J. Bradbury. 2006. Isothiazolopyridones: synthesis, structure, and biological activity of a new class of antibacterial agents. J. Med. Chem. 49:39-42.
30. Wiles, J. A., Q. Wang, E. Lucien, A. Hashimoto, Y. Song, J. Cheng, C. W. Marlor, Y. Ou, S. D. Podos, J. A. Thanassi, C. L. Thoma, M. Deshpande, M. J. Pucci, and B. J. Bradbury. 2006. Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells. Bioorg. Med. Chem. Lett. 16:1272-1276.
31. Wiles, J. A., Y. Song, Q. Wang, E. Lucien, A. Hashimoto, J. Cheng, C. W. Marlor, Y. Ou, S. D. Podos, J. A. Thanassi, C. L. Thoma, M. Deshpande, M. J. Pucci, and B. J. Bradbury. 2006. Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: in vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus. Bioorg. Med. Chem. Lett. 16:1277-1281.
32. World Health Organization. 2003. Treatment of tuberculosis. Guidelines for national programmes, 3rd ed. World Health Organization, Geneva, Switzerland.
33. World Health Organization. 2009. Global tuberculosis control: epidemiology, strategy, financing. WHO report 2009. World Health Organization, Geneva, Switzerland.